Research Article
Downregulation of mPGES-1 Expression via EGR1 Plays an Important Role in Inhibition of Caffeine on PGE<sub>2</sub> Synthesis of HBx(+)-Hepatocytes

Yan Ma, 1 Xiaoqian Wang, 1 and Nanhong Tang 1,2

1Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, 29 Xinquan Road, Fuzhou 350001, China
2Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Research Center for Molecular Medicine, Fujian Medical University, Fuzhou 350001, China

Correspondence should be addressed to Nanhong Tang; fztbh@sina.com

Received 28 February 2015; Revised 27 April 2015; Accepted 28 April 2015

1. Introduction

Hepatocellular carcinoma (HCC) is the third leading cause of death worldwide. An estimated 748,300 new liver cancer cases and 695,900 cancer deaths have been recorded worldwide in 2008 [1]. In China, most HCC patients are infected by hepatitis B virus (HBV), which undergoes a process from hepatitis to liver cirrhosis to HCC. This process is one of the significant differences between HCC and other malignant tumors. HBV, a noncytopathic specific double-stranded DNA virus, could cause acute and chronic hepatitis [2]. Hepatitis B virus x protein (HBx) has various biological functions that could be simultaneously expressed in the nucleus and cytoplasm of hepatocytes. HBx could promote the occurrence and progress of liver cirrhosis and HCC [3].

Prostaglandin E2 (PGE<sub>2</sub>) is one of the important products with the most biological activity synthesized by cyclooxygenase. PGE<sub>2</sub> is significantly increased in malignant tumor tissues and plays a critical role in HBV virus infection, as well as in the occurrence and progress of HCC [4, 5]. The synthesis of PGE<sub>2</sub> is higher in hepatocytes with positive HBx [6]. PGE<sub>2</sub> could increase the expression of oncogene in the mRNA and protein levels. The EP<sub>4</sub>/GS/AC/CREB/NF-κB molecular signaling pathways promote the growth and invasion of cancer cell [7]. Reduction of PGE<sub>2</sub> could effectively inhibit the invasion of HCC [4].

Relevant epidemiologic studies have shown that the incidence of HCC for the people who drink coffee every day is 30%–80% lower than those who do not. Caffeine has the same protective effect for chronic hepatitis B virus carriers and high-risk populations developing liver cancer [8]. A survey on 63,000 Chinese Singaporeans between the ages of 45 and 74 years conducted by the National University of Singapore shows that consumption of caffeine is negatively related to the incidence of HCC. The incidence of HCC for people who drink three cups of coffee or above every day is significantly
reduced by 44% [9]. A comparison between the 109 HBV carriers and 125 subjects in the control group collected by the Prince of Wales Hospital of Hong Kong shows that drinking coffee in moderation could reduce nearly half of the risk of HCC [8]. Some studies have shown that caffeine can effectively inhibit PGE2; however, the specific mechanism remains unclear [10]. Moreover, whether caffeine has a particular role in the regulation of PGE2 synthesis in hepatocytes with HBx expression for the study on HCC associated with HBV infection is the focus of our further investigation. Exploring the effect of caffeine on PGE2 synthesis pathways may provide a theoretical basis for the study on preventive strategies using caffeine in HBV-infected patients.

2. Materials and Methods

2.1. Material. The recombinant plasmid pcDNA3.0-HBx was constructed by our laboratory [11]. HL7702 cells (a human hepatic cell line, Institute of Biochemistry and Cell Biology, Shanghai, China), previously established HL7702-HBx cells (stable HBx expression by transfection with pcDNA3.0-HBx) [12], HepG2 cells (a human hepatocarcinoma cell line, HB-8065, ATCC, VA), and HepG2-HBx cells (stable HBx expression by transfection with pcDNA3.0-HBx) were grown in DMEM containing 10% fetal bovine serum at 37°C. The expression plasmid pGL3B-COX-2, pGL3B-628 (mPGES-1 promoter luciferase reporter plasmid, pGL3B-628 to +1), and cyclooxygenase-2 (COX-2) promoter luciferase reporter plasmid, pGL3B-COX-2, were constructed by our laboratory [13]. Caffeine solution was, respectively, added to the cell well for reaching the required final concentration.

2.2. Proliferation Assay. Briefly, 5 × 10^3 of HL7702, HL7702-HBx, HepG2, and HepG2-HBx cells were, respectively, seeded in different wells of 96-well plates and incubated overnight. Caffeine solution was, respectively, added to the different wells with a final concentration (200, 400, or 800 μM); the same amount of medium without caffeine was added to the control wells. 24 hours later, the wells of the first test point (caffeine treatment for 1 day) were washed two times by PBS and incubated with 20 μL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/mL, Sigma, St. Louis, MO) for 4 h. Formazan crystals were subsequently dissolved in 150 μL dimethyl sulfoxide (DMSO). The absorbance of the solution was measured at 490 nm and detected using the Bio-Tek IQuant Universal Microplate Spectrophotometer (Bio-Tek Instruments, Inc., Winooski, VT). For the second (caffeine treatment for 4 days) and third (caffeine treatment for 7 days) test points, the cell wells were, respectively, replaced with new culture medium (containing different concentrations of caffeine) at the third day and the sixth day after cultivation. Each treatment was repeated in triplicate.

2.3. PGE2 Analysis. Twenty-four hours after 5 × 10^3 cells/well were plated onto 96-well plates, the caffeine solution was, respectively, added with a final concentration (800 μM); the same amount of medium without caffeine was added to the control wells. One, 4, and 7 days later, the supernatant was, respectively, collected and centrifuged briefly. The amount of PGE2 in the supernatant was determined using EIA Kit (Cayman Chemical, Ann Arbor, MI) according to the manufacturer's protocol. Parallel cells were harvested and counted. All assays were performed three times.

2.4. Dual-Luciferase Reporter Assay. 2 × 10^5 of HL7702, HL7702-HBx, HepG2, and HepG2-HBx cells were, respectively, seeded in different wells of 24-well plates and incubated overnight. The supernatant was removed and replaced with serum-free medium, and DNA transfection solution containing promoter luciferase reporter plasmid and Lipofectamine 2000 (Life Technologies, Carlsbad, CA) was added to the cells, in accordance with the manufacturer's recommendations. Eight hours later, the caffeine solution was, respectively, added with a final concentration (800 μM) and it continued to be cultured for 48 h. The supernatant was removed and the cell lysates were detected for intracellular luciferase activity using Dual-Luciferase Reporter Assay System (Promega Corporation, Madison, WI) on a luminometer (Orion II Microplate Luminometer, Berthold Detection Systems, Germany) following the manufacturer's recommendations. The relative luciferase units (RLU) were obtained by comparison with control, which was set to 1. Each transfection was performed in triplicate and the data were expressed as the mean ± SD of three separate experiments.

2.5. Western Blotting. 1 × 10^5 of HL7702, HL7702-HBx, HepG2, and HepG2-HBx cells were, respectively, seeded in different wells of 6-well plates and incubated overnight. Caffeine solution was added with different final concentrations and then the plates were incubated for different time according to the experimental requirement. Cell protein was extracted by conventional method. Each treatment was repeated in triplicate. A total of 40 μg of protein was subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electrophoretic transfer to a polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA). Protein blots were incubated separately with a panel of specific antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), which included anti-mPGES-1 (1:1000, sc-12269), anti-COX-2 (1:1000, sc-19999), anti-early growth response 1 (EGR1) (1:1000), anti-peroxisome proliferator-activated receptor gamma (PPARγ) (1:1000, sc-7273), and anti-β-actin (1:4000) overnight at 4°C and then incubated with different horseradish peroxidase-(HRP-) conjugated secondary antibody at room temperature for 1 h. Visualization of the immunoreactive proteins was performed by chemiluminescence kit (BeyoECL Plus, Beyotime, Shanghai, China). Intensities of bands were quantified using the densitometric software Quantity One (Bio-Rad, Hercules, CA) and the relative intensity to internal control (β-actin) was calculated. All measurements were repeated in triplicate.
2.6. Statistical Analysis. The data were repeated at least three independent times and expressed with mean ± SD unless otherwise indicated. Assays for characterizing phenotype of cells and expression difference were analyzed by one-way analysis of variance (ANOVA) using SPSS 13.0 software package (SPSS, Inc., Chicago, IL). *P* < 0.05 denoted a statistically significant difference.

3. Results

3.1. Effect of Caffeine on Hepatocyte Proliferation and Secretion of PGE2. Caffeine with different concentrations was used to treat four strains of hepatocyte (HL7702, HL7702-HBx, HepG2, and HepG2-HBx). Figures 1(a) and 1(b) show that the inhibitory effect of caffeine on hepatocyte proliferation increased with increasing caffeine concentrations (200–800 μM) and treatment times (1–7 days), indicating that caffeine inhibits cell proliferation in a dose- and time-dependent manner. The inhibition activity of caffeine on the four strains of hepatocyte was first to be observed at the second test time point (caffeine treatment for 4 days) (*P* < 0.05). Meanwhile, the inhibition of caffeine on HL7702-HBx and HepG2-HBx cells was most obvious at the concentration of 800 μM and at the third test time point (caffeine treatment for 7 days), which was significantly higher than that on HL7702 and HepG2 cells (*P* < 0.05), respectively. Therefore, we chose 800 μM as...
Figure 2: Effect of caffeine on the expression of COX-2 and mPGES-1 in HBx positive hepatocyte. (a) Representative immunoblots for COX-2, mPGES-1, and β-actin in HL7702 and HL7702-HBx cells. (b) Representative immunoblots for COX-2, mPGES-1, and β-actin in HepG2 and HepG2-HBx cells. The group data represents the mean ± SD (n = 3). The densitometry data were normalized to β-actin. Note: * P < 0.05, statistically significant difference compared to HL7702 cells (a) or HepG2 cells (b).
the mPGES-1 promoter, thereby affecting the expression of mPGES-1.

### 3.4. Inhibition of Caffeine on the Expression of mPGES-1 through EGR1 in HBx Positive Hepatocytes

Our previous research showed that HBx could upregulate the transcription of mPGES-1 promoter through EGR1, thereby enhancing the expression of mPGES-1 in promoting the hepatocytes to secrete PGE₂ [13]. The role of EGR1 is very important in this process. Therefore, caffeine may inhibit the expression of mPGES-1 through the EGR1 pathway; that is, caffeine could inhibit the synthesis pathway of HBx-EGR1-mPGES-1-PGE₂. To verify this tentative idea, we detected the EGR1 expression of HL7702, HL7702-HBx, HepG2, and HepG2-HBx cells in the presence of caffeine (800 μM). Figure 4 shows that the EGR1 protein expression of the four strains of cells was downregulated (P < 0.05), indicating that caffeine could downregulate mPGES-1 expression by inhibiting the EGR1 expression in the hepatocytes. Meanwhile, we observed that HL7702-HBx and HepG2-HBx cells in response to caffeine stimulation were more significant than HL7702 and HepG2 cells (P < 0.05).
3.5. Effect of Caffeine on EGRI Expression through PPARγ in HBx Positive Hepatocytes. Previous studies showed the interaction of proteins between HBx and PPARγ, which inhibited the nuclear orientation of PPARγ and the DNA binding function and affects the expression of the relative growth-inhibited gene regulated by PPARγ [15]. To verify whether caffeine could affect EGRI expression by PPARγ to block the secretion of PGE2 from hepatocytes caused by HBx, we used 800 µM caffeine (a lower dose) to treat HL7702, HL7702-HBx, HepG2, and HepG2-HBx cells for 7 days. The results showed that the expression of PPARγ was increased, and the expression of PPARγ increased more significantly in the presence of HBx (P < 0.05) (Figures 5(a) and 5(b)). Approximately 5 mM caffeine (a higher dose) was further used to treat these cells for 6, 12, and 24 hours. Figures 5(c) and 5(d) show that the expression of EGRI and PPARγ did not significantly change after 6 hours of cultivation. After 12 and 24 hours, the expression of PPARγ in the case with addition of caffeine was significantly higher than that without caffeine. The increase was more significant over time (P < 0.05). Meanwhile, the EGRI expression with the addition of caffeine was significantly lower than that without caffeine; the decrease was more significant over time (P < 0.05). The changing trend of EGRI and PPARγ expression was more significant in the presence of HBx.

4. Discussion

PGE2 is one of the important products with the most biological activities synthesized by cyclooxygenase. Studies have shown that PGE2 is significantly increased in malignant tumor tissue and could promote the growth of tumor cells [16]. Therefore, inhibition of PGE2 has become one of the valuable research directions against inflammation to cancer. Currently, many drugs or compounds that could inhibit cells in producing PGE2 have been found. These drugs could destroy or affect various enzymes expression in the generation process of PGE2 [17–19]. The biosynthesis of PGE2 is regulated by phospholipase A2, cyclooxygenase (COX), and mPGES-1. Inhibition of the above-mentioned enzymes could prevent the synthesis of PGE2. Previous studies have shown that the expression level of COX-2 in tumor cells increased, and specific COX-2 inhibitor could inhibit tumor cell proliferation, induce apoptosis, and enhance the sensitivity of tumor cell to chemotherapy drugs. However, improper use
Figure 5: Effect of caffeine on EGR1 expression through PPARγ in HBx positive hepatocytes. (a) Representative immunoblots from three independent studies for PPARγ in HL7702 and HL7702-HBx cells treated with or without 800 μM caffeine for 7 days. The densitometry data were normalized to β-actin. *P < 0.05 (n = 3), statistically significant difference compared with HL7702 cells. (b) Representative immunoblots from three independent studies for PPARγ in HepG2 and HepG2-HBx cells treated with or without 800 μM caffeine for 7 days. The densitometry data were normalized to β-actin. *P < 0.05 (n = 3), statistically significant difference compared with HepG2 cells. (c) Representative immunoblots from three independent studies for EGR1 and PPARγ in HL7702 and HL7702-HBx cells treated with or without 5 mM caffeine for 6, 12, and 24 h. The densitometry data were normalized to β-actin. *P < 0.05 (n = 3), statistically significant difference compared to HL7702 cells. (d) Representative immunoblots from three independent studies for EGR1 and PPARγ in HepG2 and HepG2-HBx cells treated with or without 5 mM caffeine for 6, 12, and 24 h. The densitometry data were normalized to β-actin. *P < 0.05 (n = 3), statistically significant difference compared to HepG2 cells.
of COX-2 inhibitor could cause kidney damage and increase the incidence of cardiovascular disease and thrombus [20].

In our previous study, we found that HBx protein could regulate the transcriptional activity of mPGES-1 promoter through EGRI. During this process, PPARγ plays an important role in inhibiting the combination of EGRI and mPGES-1 promoter to prevent the transcription of mPGES-1 [13]. An interaction exists between HBx and PPARγ, which could affect the expression of the relative growth-inhibited gene regulated by PPARγ by inhibiting the nuclear orientation of PPARγ and DNA binding function to release the inhibition on cell growth [15]. 15d-PGJ₂, a ligand of PPARγ, was used to interfere in this process. The result showed that the combined action of 15d-PGJ₂, PPARγ, and EGRI could regulate the secretion of PGE₂ in the cell through mPGES-1. For hepatocytes expressed by HBx, the presence of 15d-PGJ₂ breaks the relationship between HBx and PPARγ. Activated PPARγ could inhibit the combination of EGRI and mPGES-1 promoter to prevent the transcriptional activity of mPGES-1, thereby inhibiting the occurrence of PGE₂. This finding indicates that compound intervention in the relationship between PPARγ and EGRI for affecting HBx in the expression of mPGES-1 is an effective way. Interestingly, although the relationship between proinflammatory mediator PGE₂ and liver disease has been given significant attention, studies of the influence of HBV infection on PGE₂ synthesis and the relevant intervention are rare. Therefore, we use two hepatic cell lines with different backgrounds, as well as their derived cell lines with HBx expression, to observe the characteristics of caffeine interfering in PGE₂ synthesis in HBx(+) hepatocytes.

Coffee is a common drink. Various biological activities of caffeine, the main constituent of coffee, have been widely studied. In the prevention and treatment of diseases, caffeine has a positive effect. Some studies have shown drinking coffee could reduce the risk of liver cancer. A study has shown that caffeine could enhance the sensitivity of hepatocytes to 15d-PGJ₂, PGE₂ specific inhibitor, by upregulating the expression of PPARγ receptor in hepatocytes. Caffeine could also promote the degradation of SMAD2 and inhibit phosphorylation of SMAD1 and SMAD2 [21]. The above-mentioned effects of caffeine downregulate the hepatic fibrosis-related connective tissue growth factor of inflammatory cytokines induced by TGF-β (CCTG), thereby inhibiting the progress of hepatic fibrosis. The interaction between caffeine and mPGES-1 has not been reported yet. In this paper, we found that the mPGES-1 and EGRI expression and mPGES-1 promoter activity in the hepatocytes treated by caffeine are significantly lower than those of the group without caffeine. The expression of PPARγ was significantly higher than that of the group without caffeine. These changes are more significant in HBx(+) hepatocytes. Therefore, we speculated that caffeine has an effect similar to 15d-PGJ₂, which could release the binding of HBx and PPARγ in DBA hinge regions and activate PPARγ, to play the role of PPARγ in the inhibition of cell growth. Moreover, we also found that caffeine has insignificant effect on COX-2 expression and promoter transcription of PGE₂ biosynthetic enzymes. That is, caffeine does not have side effects similar to COX-2 inhibitor-like drugs in inhibiting HCC growth. In addition, the potential adverse

side effects caused by inhibition of normal levels of PGE₂ produced by hepatocytes must be taken into consideration. Based on our current experiments in vitro using low concentration of caffeine, we speculated that the side effects of PGE₂ inhibition by caffeine may be fewer; however, the exact effects should be verified in animal experiments in the future.

Apparently, our study reveals that caffeine could effectively reduce PGE₂ synthesis in HBx(+) hepatocytes by specifically blocking the PPARγ-EGRI-mPGES-1 pathway and delay the effect of PGE₂ in promoting HCC growth, which provides a new evidence of molecular biology for the hypothesis that drinking coffee is beneficial to HBV-infected patients.

Conflict of Interests
None of the authors have any conflict of interests to disclose.

Acknowledgments
This work was supported by the Professor’s Academic Development Foundation of Fujian Medical University (no. JS11004) and the Construction Project of National Key Clinical Subject of General Surgery.

References
[1] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011.
[2] M. Tarocchi, S. Polvani, G. Marroncini, and A. Galli, “Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis,” World Journal of Gastroenterology, vol. 20, pp. 11630–11640, 2014.
[3] X. D. Zhang, Y. Wang, and L. H. Ye, “Hepatitis B virus X protein accelerates the development of hepatoma,” Cancer Biology & Medicine, vol. 11, no. 3, pp. 182–190, 2014.
[4] H. Xie, L. Gao, N. Chai et al., “Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib,” Molecular carcinogenesis, vol. 48, no. 1, pp. 56–65, 2009.
[5] M. Zhang, H. Zhang, S. Cheng et al., “Prostaglandin E2 accelerates invasion by upregulating Snail in hepatocellular carcinoma cells,” Tumor Biology, vol. 35, no. 7, pp. 7135–7145, 2014.
[6] C. Shan, F. Xu, S. Zhang et al., “Hepatitis B virus X protein promotes liver cell proliferation via a positive cascade loop involving arachidonic acid metabolism and p-ERK1/2,” Cell Research, vol. 20, no. 5, pp. 563–575, 2010.
[7] H. Zhang, S. Cheng, M. Zhang et al., “Prostaglandin e2 promotes hepatocellular carcinoma cell invasion through upregulation of YB-1 protein expression,” International Journal of Oncology, vol. 44, no. 3, pp. 769–780, 2014.
[8] W. W.-M. Leung, S. C. Ho, H. L. Y. Chan, V. Wong, W. Yeo, and T. S. K. Mok, “Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study,” Journal of Epidemiology and Community Health, vol. 65, no. 6, pp. 556–558, 2011.
[9] S. Johnson, W.-P. Koh, R. Wang, S. Govindarajan, M. C. Yu, and J.-M. Yuan, “Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese
Mediators of Inflammation

Health Study,” Cancer Causes and Control, vol. 22, no. 3, pp. 503–510, 2011.

[10] R. Ulcar, R. Schuligoi, A. Heinemann, B. Santner, and R. Amann, “Inhibition of prostaglandin biosynthesis in human endotoxin-stimulated peripheral blood monocytes: effects of caffeine,” Pharmacology, vol. 67, no. 2, pp. 67–71, 2003.

[11] H.-Y. Chen, N.-H. Tang, N. Lin, Z.-X. Chen, and X.-Z. Wang, “Hepatitis B virus X protein induces apoptosis and cell cycle deregulation through interfering with DNA repair and checkpoint responses,” Hepatology Research, vol. 38, no. 2, pp. 174–182, 2008.

[12] J. Teng, X. Wang, Z. Xu, and N. Tang, “HBx-dependent activation of twist mediates STAT3 control of epithelium-mesenchymal transition of liver cells,” Journal of Cellular Biochemistry, vol. 114, no. 5, pp. 1097–1104, 2013.

[13] C. Liu, S. Chen, X. Wang, Y. Chen, and N. Tang, “15d-PGJ2 decreases PGE2 synthesis in HBx-positive liver cells by interfering EGR1 binding to mPGES-1 promoter,” Biochemical Pharmacology, vol. 91, pp. 337–347, 2014.

[14] A. C. P. de Oliveira, E. Cadelario-Jalil, H. S. Bhatia, K. Lieb, M. Hult, and B. L. Fiebich, “Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2,” Glia, vol. 56, no. 8, pp. 844–855, 2008.

[15] Y.-H. Choi, H.-I. Kim, J. K. Seong et al., “Hepatitis B virus X protein modulates peroxisome proliferator-activated receptor γ through protein–protein interaction,” FEBS Letters, vol. 557, no. 1–3, pp. 73–80, 2004.

[16] M. Hughes-Fulford, C.-F. Li, J. Boonyaratanakornkit, and S. Sayyah, “Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer,” Cancer Research, vol. 66, no. 3, pp. 1427–1433, 2006.

[17] Q. Wu, W. Chang, C.-C. Zhu, L.-R. Fan, and S.-Z. Song, “Effect of NS-398 on cyclooxygenase-2 expression and proliferation of HepG2 cells,” Zhonghua Yu Fang Yi Xue Za Zhi, vol. 42, no. 4, pp. 260–263, 2008.

[18] B. Zhong, H. Shen, X. Sun, H. Wang, Y. Zhang, and Z. Sun, “Additive effects of ulinastatin and docetaxel on growth of breast cancer xenograft in nude mice and expression of PGE2, IL-10, and IL-2 in primary breast cancer cells,” Cancer Biotherapy and Radiopharmaceuticals, vol. 27, no. 4, pp. 252–258, 2012.

[19] T. Morisaki, M. Umebayashi, A. Kiyota et al., “Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells In Vitro,” Anticancer Research, vol. 33, no. 4, pp. 1387–1396, 2013.

[20] I. L. P. Beales and O. O. Ogunwobi, “Microsomal prostaglandin e synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production,” International Journal of Cancer, vol. 126, no. 9, pp. 2247–2255, 2010.

[21] O. A. Gressner, B. Lahme, K. Rehbein, M. Siluschek, R. Weiskirchen, and A. M. Gressner, “Pharmacological application of caffeine inhibits TGF-β-stimulated connective tissue growth factor expression in hepatocytes via PPARγ and SMAD2/3-dependent pathways,” Journal of Hepatology, vol. 49, no. 5, pp. 758–767, 2008.